Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies

NCT00104923 is registered in ClinicalTrials.gov with California Cancer Consortium as lead sponsor.

NCT NCT00104923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00104923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Hematologic Malignancies
Lead sponsor
California Cancer Consortium
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2005
Completion date
April 30, 2017
Enrollment
29 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloproliferative disorders, leukemia, lymphoma, multiple myeloma and plasma cell neoplasm